Loyal | First Round

Loyal

Imagine if we had more time with the dogs we love.

Loyal is a clinical-stage animal health company developing longevity drugs for dogs. By targeting the underlying mechanisms of aging, Loyal hopes to extend the lifespan of dogs and improve their quality of life as they age.

As a solo-founder, Celine has put an outlier level of grit and effort into willing this deep tech company into existence. With over $150M raised, the team currently has three drugs in development and is making progress toward approval from the FDA’s Center for Veterinary Medicine.

Founder: Celine Halioua
Initial Partnership: Seed
Category: Healthcare
Partner: Josh Kopelman
Location: SF Bay Area

Celine Halioua's recent interview on clearing a key FDA hurdle

Read The Washington Post story here